Digene strengthens diagnostic patents:
This article was originally published in Clinica
Executive Summary
US diagnostics company Digene has received a European patent for its Hybrid Capture technology. All of the company's tests are based on this technology, which uses signal amplification to detect as few as 100 molecules of DNA or RNA in a rapid format. The patent strengthens the company's protection for its human papillomavirus products and core technology, according to Beltsville, Maryland-based Digene.